Developing a therapeutic anti-dendritic cell antibody to prevent graft versus host disease
| Data(s) |
2009
|
|---|---|
| Resumo |
Host and donor dendritic cells (DC) stimulate alloreactive donor T lymphocytes, and initiate GVHD. We have shown that polyclonal antibody to the DC surface activation marker human CD83 (anti hCD83), which depletes activated DC, can prevent human DC and T cell induced lethal xenogeneic GVHD in SCID mice without impairing T cell mediated anti-leukaemic and anti-viral (CMV and influenza) immunity (J Exp Med 2009; 206: 387). Therefore, we made and tested a polyclonal anti mouse CD83 (RAM83) antibody in murine HSCT models and developed a human mAb against hCD83 as a potential new therapeutic immunosuppressive agent. |
| Identificador | |
| Relação |
https://ash.confex.com/ash/2009/webprogram/Paper23420.html Hart, Derek, Seldon, Therese, Jones, Martina, Sheng, Yonghua, Palkova, Anna, Cullup, Hannah, Munro, Trent, Sinfield, Laura, Rice, Alison M., Wilson, John, Gray, Peter, Barnard, Ross, Mahler, Stephen, & Munster, David J. (2009) Developing a therapeutic anti-dendritic cell antibody to prevent graft versus host disease. In 51st Annual Meeting of the American Society of Hematology, 5-8 December 2009, New Orleans, USA. |
| Fonte |
Faculty of Health |
| Tipo |
Conference Item |
